In summary, our study identified various, novel oncogenic EGFR interactors, and one of them, TACC3, is a potential drug target for NSCLC and could be targeted concomitantly with EGFR in order to potentiate current treatment or overcome acquired TKI resistance. Here, TACC3 is linked to non-small cell lung carcinoma.